The data were statistically significant, but the market had been hoping for more.
But AZD7442 still has two more bites at the cherry.
A second clinical failure means that Biogen threw away $877m, but this sum will today be seen as little more than a rounding error.
But this week three transactions did squeak through.
Biogen needs blood tests for amyloid beta to progress quickly – and several are in the pipeline.
Paying $1.1bn for Heartware five years ago was not the company’s smartest move.
The anti-Tigit MAb domvanalimab will generate key clinical results any day; will they be good enough for Gilead to opt in?
Next month the FDA will determine Biogen’s fate in Alzheimer’s, while Ascendis and Novo Nordisk also await Pdufa decisions.
If imminent results of Sanofi’s amcenestrant in Ameera-3 are positive Serds could finally see late-stage validation.
Awaiting crucial pivotal data, company reckons its plant-generated Covid-19 vaccine can still make a contribution to the pandemic.
The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.
The German tech investor Kizoo Ventures is committing €300m of its own cash to biotech start-ups working on rejuvenation and healthy lifespan expansion.